Expert Review of Anti-infective Therapy最新文献_第3页

Adult vaccinations against respiratory infections.

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2025-02-01 Epub Date: 2025-01-31 DOI: 10.1080/14787210.2025.2457464

Antoni Torres, Catia Cilloniz, Marta Aldea, Guillermo Mena, José M Miró, Antoni Trilla, Ana Vilella, Rosario Menéndez

{"title":"Adult vaccinations against respiratory infections.","authors":"Antoni Torres, Catia Cilloniz, Marta Aldea, Guillermo Mena, José M Miró, Antoni Trilla, Ana Vilella, Rosario Menéndez","doi":"10.1080/14787210.2025.2457464","DOIUrl":"10.1080/14787210.2025.2457464","url":null,"abstract":"Introduction: Lower respiratory infections have a huge impact on global health, especially in older individuals, immunocompromised people, and those with chronic comorbidities. The COVID-19 pandemic highlights the importance of vaccination. However, there are lower rates of vaccination in the adult population that are commonly due to a missed opportunity to vaccinate. Vaccination offers the best strategy to prevent hospitalization, complications, and death caused by lower respiratory infections.Areas covered: In this review, the authors provide an overview of the vaccines for lower respiratory infections in the adult population. The review highlights the available data about the impact of vaccines on preventing respiratory infections, focusing on the pneumococcal vaccine, influenza vaccine, COVID-19 vaccines, and respiratory syncytial virus (RSV) vaccines. The authors discuss the currently available scientific evidence on the role of vaccines against respiratory infections. Finally, the authors review the current recommendations for vaccines in the adult population.Expert opinion: Scientific evidence on the effectiveness of vaccines against respiratory infections is important. An efficient implementation of adult immunization strategies will provide an opportunity to decrease the global burden of lower respiratory infections. Recognizing the existing vaccines and their recommendations for the adult population is essential to achieve a high vaccination rate in the population.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"135-147"},"PeriodicalIF":4.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143028481","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The serological dilemma: rethinking syphilis treatment evaluation.

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2025-02-01 Epub Date: 2025-02-18 DOI: 10.1080/14787210.2025.2467646

Jiangchen Yao, Peng Ling, Xuan Ding, Xiaohong Zhang, Ting Lin, Yongjian Xiao, Shuangquan Liu, Feijun Zhao

{"title":"The serological dilemma: rethinking syphilis treatment evaluation.","authors":"Jiangchen Yao, Peng Ling, Xuan Ding, Xiaohong Zhang, Ting Lin, Yongjian Xiao, Shuangquan Liu, Feijun Zhao","doi":"10.1080/14787210.2025.2467646","DOIUrl":"10.1080/14787210.2025.2467646","url":null,"abstract":"Introduction: Nontreponemal tests (NTT) constitute a significant method in syphilis detection, playing a crucial role in screening, diagnosing, and monitoring disease activity. However, recent discussions have cast doubt on the traditional belief that NTT are suitable for evaluating treatment efficacy, as inconsistencies between NTT results and syphilis treatment outcomes have been observed with some frequency.Areas covered: We have delineated the current status of serological methods for evaluating the therapeutic efficacy of syphilis treatment and summarized and discussed the exploration of biomarkers for syphilis therapy. A literature search was conducted in PubMed over all available dates for relevant published papers and conference abstracts with the search terms, 'Syphilis,' 'Treponema pallidum,' 'Serofast,' 'Treatment efficacy evaluation,' 'Nontreponemal,' 'RPR,' 'TRUST,' 'VDRL,' 'Neurosyphilis,' 'Pregnant syphilis,' 'Congenital syphilis,' 'Reinfection,' 'Cardiolipin,' 'Serology.'Expert opinion: Currently, the assessment of treatment efficacy through serological methods is limited to the use of the NTT. Therefore, it is imperative for clinicians to gain a deeper understanding of the significance and limitations of the NTT, as well as a focus on exploring more potential indicators for evaluating treatment efficacy.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"181-195"},"PeriodicalIF":4.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143406505","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comparison of tegoprazan and proton pump inhibitors for first-line Helicobacter pylori eradication: a systematic review with meta-analysis.

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2025-02-01 Epub Date: 2025-01-29 DOI: 10.1080/14787210.2025.2459722

Jun-Hyung Cho, So-Young Jin, Suyeon Park

{"title":"Comparison of tegoprazan and proton pump inhibitors for first-line Helicobacter pylori eradication: a systematic review with meta-analysis.","authors":"Jun-Hyung Cho, So-Young Jin, Suyeon Park","doi":"10.1080/14787210.2025.2459722","DOIUrl":"10.1080/14787210.2025.2459722","url":null,"abstract":"Background: Tegoprazan (TPZ), a potassium-competitive acid blocker with potent gastric acid-suppressing activity, may be a potential agent for treating Helicobacter pylori infection. The study aimed to evaluate the efficacy of TPZ-based therapy for H. pylori eradication compared with proton pump inhibitor (PPI)-based therapy.Research design and methods: A comprehensive literature search was conducted up to August 2024 using PubMed, Embase, and the Cochrane Library to investigate the beneficial effects of TPZ-based therapy for H. pylori eradication. Studies that evaluated the eradication rates between the TPZ- and PPI-based therapies were included. The authors conducted a meta-analysis to calculate the eradication rate and pooled risk ratio (RR) with a 95% confidence interval.Results: Seven studies involving 3200 patients were included. H. pylori eradication rates did not differ significantly between the TPZ- and PPI-based therapies based on the intention-to-treat (77.3% vs. 76.4%, p = 0.68; pooled RR = 1.01 [0.97-1.05]) and per-protocol (84.3% vs. 84.2%, p = 0.69; pooled RR = 1.01 [0.98-1.04]) analyses. Additionally, no significant difference was observed in the adverse drug events between TPZ- and PPI-based therapies (27.2% vs. 30.8%, p = 0.26; pooled RR = 0.91 [0.76-1.08]).Conclusions: H. pylori eradication and adverse drug event rates with TPZ- and PPI-based treatments were similar.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"227-233"},"PeriodicalIF":4.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143037750","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Current role of ceftobiprole in the treatment of hospital-acquired and community-acquired pneumonia: expert opinion based on literature and real-life experiences.

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2025-02-01 Epub Date: 2025-02-05 DOI: 10.1080/14787210.2025.2461552

Ivan Gentile, Simone Giuliano, Silvia Corcione, Francesco Giuseppe De Rosa, Marco Falcone, Daniele Roberto Giacobbe, Alberto Enrico Maraolo, Claudio Maria Mastroianni, Alessandra Oliva, Renato Pascale, Carlo Tascini, Giusy Tiseo, Pierluigi Viale, Matteo Bassetti

{"title":"Current role of ceftobiprole in the treatment of hospital-acquired and community-acquired pneumonia: expert opinion based on literature and real-life experiences.","authors":"Ivan Gentile, Simone Giuliano, Silvia Corcione, Francesco Giuseppe De Rosa, Marco Falcone, Daniele Roberto Giacobbe, Alberto Enrico Maraolo, Claudio Maria Mastroianni, Alessandra Oliva, Renato Pascale, Carlo Tascini, Giusy Tiseo, Pierluigi Viale, Matteo Bassetti","doi":"10.1080/14787210.2025.2461552","DOIUrl":"10.1080/14787210.2025.2461552","url":null,"abstract":"Introduction: Community-acquired pneumonia (CAP) and hospital-acquired pneumonia (HAP) are major global health challenges, with high morbidity and mortality rates. The increasing prevalence of multidrug-resistant (MDR) bacteria may diminish the effectiveness of standard empirical antibiotics, highlighting the need for broader-spectrum agents that target also MDR organisms.Areas covered: This review summarizes findings from a PubMed search on the use of ceftobiprole in CAP and HAP. It highlights key features of ceftobiprole, including its mechanism of action and broad spectrum of activity against multiple MDR pathogens. Clinical data from randomized controlled trials and real-world studies underscore its non-inferiority to standard treatments, with favorable safety profile and high clinical cure rates even in challenging cases.Expert opinion: Ceftobiprole represents a valid option for the patients with CAP and HAP. Its main advantages include its broad spectrum of activity, making it a valuable therapeutic choice for treating polymicrobial infections, and its favorable safety profile, which makes it a good candidate in elderly patients with multiple comorbidities and polypharmacy. Caution is advised in patients at high risk of ESBL-producing organisms or MDR Pseudomonas aeruginosa infections, where combination therapy is recommended. Moreover, therapeutic drug monitoring is recommended to improve outcomes, particularly in complex clinical conditions.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"217-225"},"PeriodicalIF":4.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143064834","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Assessment of potentially unnecessary antibiotic use for suspected urinary tract infections in nursing homes using a simplified algorithm. 使用简化算法评估养老院疑似尿路感染可能不必要的抗生素使用。

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2025-02-01 Epub Date: 2025-01-26 DOI: 10.1080/14787210.2025.2456860

Carl Llor, Jonas Olsen, Jesper Lykkegaard, Marilena Anastasaki, Jette Nygaard Jensen, Jens Søndergaard, Valeria Antsupova, Davorina Petek, Malene Plejdrup Hansen, Marie Theut, Christos Lions, Lina Jaruseviciene, Ruta Radzeviciene, András Bálint, Helena Glasova, Jozef Glasa, Nina Sodja, Ana Moragas, Ramon Monfà, Ana García-Sangenís, Anna Kowalczyk, Georg Ruppe, Laura Vallejo-Torres, Marina Elistratova, Beatriz González López-Valcárcel, Greta Tsoulchai

{"title":"Assessment of potentially unnecessary antibiotic use for suspected urinary tract infections in nursing homes using a simplified algorithm.","authors":"Carl Llor, Jonas Olsen, Jesper Lykkegaard, Marilena Anastasaki, Jette Nygaard Jensen, Jens Søndergaard, Valeria Antsupova, Davorina Petek, Malene Plejdrup Hansen, Marie Theut, Christos Lions, Lina Jaruseviciene, Ruta Radzeviciene, András Bálint, Helena Glasova, Jozef Glasa, Nina Sodja, Ana Moragas, Ramon Monfà, Ana García-Sangenís, Anna Kowalczyk, Georg Ruppe, Laura Vallejo-Torres, Marina Elistratova, Beatriz González López-Valcárcel, Greta Tsoulchai","doi":"10.1080/14787210.2025.2456860","DOIUrl":"10.1080/14787210.2025.2456860","url":null,"abstract":"Background: Nursing home (NH) residents are frequently treated with antibiotics for urinary tract infections (UTIs), often due to overdiagnosis. The aim of this study was to evaluate the proportion of potentially unnecessary antibiotic use for suspected UTIs in NHs across eight European countries.Research design and methods: Over a three-month period (February to April 2024), NH professionals recorded information on all antibiotic treatments for UTIs using a specific registration chart. Based on medical literature and the expertise of the project consortium members, the authors developed and endorsed by consensus a simplified algorithm to assess unnecessary antibiotic use in residents without indwelling catheters.Results: The study, conducted across 110 NHs, included 2773 antibiotic-treated infections. Of these, 1158 (41.8%) were treated for UTIs. Among 975 UTI cases without catheters, 54.1% may have been unnecessarily treated. Over one-third involved nonspecific symptoms including poor general condition and changes in urine appearance, while specific urinary symptoms, such as incontinence (21.3%) and dysuria (20.8%), were less common. A trend toward greater, potentially unnecessary antibiotic use was observed when urine dipsticks were performed.Conclusions: The findings reveal potentially unnecessary antibiotic use. Further algorithm validation is needed to enhance diagnostic criteria, reduce overuse, and improve UTI management in NHs.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"235-241"},"PeriodicalIF":4.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143002888","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Mistakes to avoid in the management of abdominal tuberculosis.

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2025-02-01 Epub Date: 2025-02-23 DOI: 10.1080/14787210.2025.2468331

Abhirup Chatterjee, Daya Krishna Jha, Aravind Sekar, Vishal Sharma

{"title":"Mistakes to avoid in the management of abdominal tuberculosis.","authors":"Abhirup Chatterjee, Daya Krishna Jha, Aravind Sekar, Vishal Sharma","doi":"10.1080/14787210.2025.2468331","DOIUrl":"10.1080/14787210.2025.2468331","url":null,"abstract":"Introduction: The diagnosis and management of abdominal tuberculosis, i.e Gastrointestinal Tuberculosis (GITB) and tuberculous peritonitis (TBP) is challenging. Abdominal tuberculosis, presenting usually with abdominal pain, intestinal obstruction, and constitutional symptoms, is typically a paucibacillary condition. The diagnosis hinges on a correct interpretation of clinical, radiological, histological, biochemical, and microbiological findings as also appropriately assessing response to therapy.Areas covered: The authors review potential missteps that could occur in managing GITB and TBP sourced from published literature and clinical experience. These include avoiding excess use of tests with limited accuracy, understanding limitations of ascitic adenosine deaminase (ADA) and granulomas, avoiding empirical antitubercular therapy (ATT) where possible but also understanding that microbiological tests may not always be positive, and finally not to bank solely on subjective clinical responses but to use objective markers in assessing response to therapy. In addition, diagnosis of predisposing immunosuppressed states, attention to nutrition, appropriate management of sequelae with endoscopic dilatation/surgery, and early surgery when indicated are some of the additional issues discussed.Expert opinion: In future, a more secure diagnosis banking on the use of better microbiological tools, multiparameter-based models, artificial intelligence-based approaches, and use of advances in -omics-based approaches can improve diagnosis and avoid some missteps.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"197-215"},"PeriodicalIF":4.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143425402","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Unraveling sulbactam-durlobactam: insights into its role in combating infections caused by Acinetobacter baumannii. 解开舒巴坦-杜罗巴坦：洞察其在对抗鲍曼不动杆菌引起的感染中的作用。

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2025-01-01 Epub Date: 2024-12-19 DOI: 10.1080/14787210.2024.2440018

Yakun Fu, Tomefa E Asempa, Joseph L Kuti

{"title":"Unraveling sulbactam-durlobactam: insights into its role in combating infections caused by Acinetobacter baumannii.","authors":"Yakun Fu, Tomefa E Asempa, Joseph L Kuti","doi":"10.1080/14787210.2024.2440018","DOIUrl":"10.1080/14787210.2024.2440018","url":null,"abstract":"Introduction: Carbapenem-resistant Acinetobacter baumannii (CRAB) is a critical priority pathogen posing a substantial threat to our public health due to its virulence and resistance to broad-spectrum antimicrobials. Sulbactam-durlobactam (Xacduro) is a newly approved β-lactam-β-lactamase inhibitor combination agent with potent in vitro and in vivo activity against CRAB. The phase III randomized trial (ATTACK) demonstrated the safety and efficacy of sulbactam-durlobactam in combination with imipenem-cilastatin as background therapy in treating adult patients with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by CRAB.Areas covered: This review will discuss pharmacology, antimicrobial activity, pharmacokinetics/pharmacodynamics, clinical efficacy, safety, and therapeutic role of sulbactam-durlobactam. To gather relevant information, a literature search was performed using PubMed and Google Scholar electronic databases. Search terms used include sulbactam, sulbactam-durlobactam, ETX2514, Acinetobacter baumannii, Acinetobacter baumannii-calcoaceticus complex, CRAB, OXA-24, and OmpA. Additional information was obtained from the sulbactam-durlobactam FDA package insert and infectious diseases conference abstracts.Expert opinion: Sulbactam-durlobactam is a well-tolerated β-lactam-β-lactamase inhibitor combination agent with efficacy against CRAB. Given the limitations of alternative treatment options, sulbactam-durlobactam may also be considered as a treatment option for non-respiratory infections caused by CRAB, however further clinical studies are warranted.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"67-78"},"PeriodicalIF":4.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142791346","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Targeting H3N2 influenza: advancements in treatment and vaccine strategies. 针对 H3N2 流感：治疗和疫苗策略的进展。

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2025-01-01 Epub Date: 2025-01-03 DOI: 10.1080/14787210.2024.2443920

Shriyansh Srivastava, Nandani Jayaswal, Sachin Kumar, G S N Koteswara Rao, Roja Rani Budha, Aroop Mohanty, Rachana Mehta, Vasso Apostolopoulos, Sanjit Sah, D Katterine Bonilla-Aldana, Ricardo Ulloque-Badaracco, Alfonso J Rodriguez-Morales

{"title":"Targeting H3N2 influenza: advancements in treatment and vaccine strategies.","authors":"Shriyansh Srivastava, Nandani Jayaswal, Sachin Kumar, G S N Koteswara Rao, Roja Rani Budha, Aroop Mohanty, Rachana Mehta, Vasso Apostolopoulos, Sanjit Sah, D Katterine Bonilla-Aldana, Ricardo Ulloque-Badaracco, Alfonso J Rodriguez-Morales","doi":"10.1080/14787210.2024.2443920","DOIUrl":"10.1080/14787210.2024.2443920","url":null,"abstract":"Introduction: The emergence of the H3N2 influenza virus in 1968 marked a significant event as it crossed the species barrier. This shift led to a pandemic, resulting in the deaths of one million people globally and highlighting the virus's severe impact on older individuals due to antigenic drift.Area covered: This review comprehensively examines the virological characteristics, evolutionary trends, and global epidemiology of the Influenza A (H3N2) virus. It delves into vaccination strategies, antiviral interventions, and emerging diagnostic approaches. The impact of antigenic variation on vaccine design and effectiveness, seasonal outbreak patterns, and pandemic potential are explored. Additionally, the interplay between viral factors and host immune responses is assessed. Researchers are actively investigating innovative strategies to enhance vaccine efficacy against H3N2 mutations, such as precise antigenic material administration, controlled release patterns, understanding immune system mechanisms, and glycan engineering.Expert opinion: The ongoing mutational dynamics of the H3N2 virus necessitate regular vaccine updates, as advocated by the WHO. Research in the Western Pacific region underscores the need for heightened awareness and effective control strategies. Evaluating antiviral therapies and addressing drug resistance requires multidisciplinary approaches involving researchers, healthcare professionals, and policymakers. This comprehensive understanding of H3N2 is vital for improving public health interventions and preparing for future influenza challenges.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"5-18"},"PeriodicalIF":4.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142834857","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Mechanisms of resistance to cell wall and plasma membrane targeting antifungal drugs in Candida species isolated in Africa. 非洲念珠菌对细胞壁和质膜靶向抗真菌药物的耐药性机制。

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2025-01-01 Epub Date: 2025-01-06 DOI: 10.1080/14787210.2024.2448844

Chibuike Ibe, Akaninyene Otu, Carolina Henritta Pohl

{"title":"Mechanisms of resistance to cell wall and plasma membrane targeting antifungal drugs in Candida species isolated in Africa.","authors":"Chibuike Ibe, Akaninyene Otu, Carolina Henritta Pohl","doi":"10.1080/14787210.2024.2448844","DOIUrl":"10.1080/14787210.2024.2448844","url":null,"abstract":"Introduction: There is a rise in the emergence of multidrug resistant fungal pathogens worldwide, including in Africa.Method: This systematic review summarized the published data on the mechanisms and epidemiology of antifungal resistance in Candida species in Africa between 2000 and early 2024.Result: Seventeen reports from seven African countries were analyzed but due to the paucity of data, the prevalence of antifungal resistant Candida isolates in Africa could not be estimated. However, a total of 1376 (out of 2812) resistant isolates were documented with South Africa reporting the most. Candida auris was the most reported species with multidrug and pandrug resistant strains documented in South Africa. Generally, azoles but not posaconazole or isavuconazole, resistance was reported. Fluconazole resistant isolates harbored Erg11 Y132F, VF125LA and K177A/R/N335S/E343D substitutions, MRR1 gain of function mutations or efflux pump protein over expression. Resistance to members of the echinocandin family was also reported and Fks1 S639P substitution was observed.Conclusion: The data highlight that the increasing Candida species resistance to cell wall and cell membrane active antifungals is a cause for serious concern in Africa. There is need to increase antifungal research capacity and mount epidemiological surveillance to determine the true scale of the problem.Prospero registration number: CRD42024550231.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"91-104"},"PeriodicalIF":4.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142926962","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Hypoalbuminemia as a predictor of severe dengue: a systematic review and meta-analysis. 低白蛋白血症作为严重登革热的预测因子：一项系统回顾和荟萃分析。

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2025-01-01 Epub Date: 2025-01-04 DOI: 10.1080/14787210.2024.2448721

Muhammed Shabil, Ganesh Bushi, Vasso Apostolopoulos, Tahani Alrahbeni, Khalid Al-Mugheed, Mahalaqua Nazli Khatib, Shilpa Gaidhane, Quazi Syed Zahiruddin, Neelima Kukreti, Sarvesh Rustagi, Yousef N Alhashem, Jawaher Alotaibi, Nawal A Al Kaabi, Tarek Sulaiman, Hussain R Alturaifi, Faryal Khamis, Ali A Rabaan, Prakasini Satapathy

{"title":"Hypoalbuminemia as a predictor of severe dengue: a systematic review and meta-analysis.","authors":"Muhammed Shabil, Ganesh Bushi, Vasso Apostolopoulos, Tahani Alrahbeni, Khalid Al-Mugheed, Mahalaqua Nazli Khatib, Shilpa Gaidhane, Quazi Syed Zahiruddin, Neelima Kukreti, Sarvesh Rustagi, Yousef N Alhashem, Jawaher Alotaibi, Nawal A Al Kaabi, Tarek Sulaiman, Hussain R Alturaifi, Faryal Khamis, Ali A Rabaan, Prakasini Satapathy","doi":"10.1080/14787210.2024.2448721","DOIUrl":"10.1080/14787210.2024.2448721","url":null,"abstract":"Introduction: Dengue fever is a significant health concern globally, especially in tropical regions. Identifying reliable markers for severe dengue, such as hypoalbuminemia, is crucial for early diagnosis and treatment.Methods: This review systematically explores the association between hypoalbuminemia and severe dengue. We searched databases including PubMed, Embase, Scopus, Cochrane, and Web of Science until 28 December 2023, focusing on studies that reported albumin levels in dengue patients. Our selection criteria aimed at observational studies, from which data extraction and quality assessment were performed using Nested- Knowledge and the Newcastle-Ottawa Scale.Results: A meta-analysis of 17 studies involving 974 severe and 18,496 non-severe dengue patients identified a standardized mean difference (SMD) in albumin levels of -1.625 g/dL (95% CI: -3.618 to -0.369). Subgroup analysis indicated more pronounced hypoalbuminemia in pediatric patients, with a pooled SMD of -1.08 g/dL (95% CI: -1.71 to -0.45). Our analysis demonstrated the link between hypoalbuminemia and severe dengue, indicating a significant pooled relative risk of 2.286, within 95% CI 1.308 to 3.996.Conclusions: The study confirms hypoalbuminemia as a significant predictor of severe dengue. Recognizing hypoalbuminemia in dengue patients can aid clinicians in forecasting the severity, potentially improving patient outcomes through targeted therapeutic strategies.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"105-118"},"PeriodicalIF":4.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142914067","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0